Tevogen Bio Holdings Inc.

Tevogen Bio Holdings Inc. (Nasdaq: TVGN) is a clinical-stage biopharmaceutical company focused on developing off-the-shelf allogeneic T-cell receptor therapies targeting infectious diseases and oncology. The company became publicly traded in 2023 following the completion of its SPAC business combination, after which it began filing periodic reports with the SEC as an operating entity in the biotechnology sector. Its November 13, 2023 Form 10-Q reflects the company's early post-merger public status, with operations centered on advancing its TVGN-489 program and related T-cell therapy pipeline through clinical development. For complete filing history, sponsor details, and deal analytics on TVGN, sign up for full access at SpacDesk.